GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

CRDF · Sep 30, 2025

Cardiff Oncology, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001193125-25-269424General Corporate
Capex intensity36thOwn-history percentile · N=11
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

15.00% · OPTIONAL · VALID

Operating cash generation15thOwn-history percentile · N=13
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-9028.33% · OPTIONAL · VALID

Revenue growth11thOwn-history percentile · N=9
Evidence method

Yoy · gp.fundamentals.revenue

-27.27% · CORE · VALID

Operating margin46thOwn-history percentile · N=13
Evidence method

Level · gp.fundamentals.operating_margin

-9978.33% · CORE · VALID

SBC intensity62thOwn-history percentile · N=13
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

1153.33% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History13 statesSelf-history eligible
Period transition

What moved in the state?

Cash Generation Decreased
Previous
-6882.64%
Current
-9028.33%
Delta
-2145.69%
Growth Decreased
Previous
-25.77%
Current
-27.27%
Delta
-1.51%
Profitability Increased
Previous
-12212.40%
Current
-9978.33%
Delta
2234.06%
Sbc Intensity Decreased
Previous
1390.91%
Current
1153.33%
Delta
-237.58%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.